Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2022 - 07:00 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Epizyme Jerald Korn , the Company’s Chief Operating Officer, with a grant date of April 1, 2022 , as equity inducement awards outside of the Company’s 2013 Stock Incentive Plan and material to Mr. Korn’s acceptance of employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Mr. Korn received options to purchase an aggregate of 800,000 shares of Epizyme common stock. The options have an exercise price of $1.14 Epizyme common stock on April 1, 2022 , the grant date of the options. The options will vest as to 25% of the underlying shares on the first anniversary of the grant date and as to an additional 2.0833% of the shares at the end of each successive month following the first anniversary of the grant date, such that the shares underlying the options granted to Mr. Korn will be fully vested on the fourth anniversary of the grant date, subject to Mr. Korn’s continued employment with Epizyme on such vesting dates.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220406005019/en/
Media:
Erin Graves
media@epizyme.com
Investors:
Caitlin Stern
cstern@realchemistry.com
Source: Epizyme, Inc.
EPZM Rankings
N/A Ranked by Stock Gains
EPZM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About EPZM
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
